Sponsor Pipeline

Travere Therapeutics, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
7
Active Trials
4
Recruiting
3
Phase 3
7
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-11 NCT03406611
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known…
Enrollment reopened
2026-08-11 NCT03406611
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known…
Primary endpoint(s) modified
2026-08-11 NCT03406611
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known…
Enrollment increased: 32 -> 39 participants
2026-08-11 NCT03406611
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known…
Trial arms changed: 2 -> 3
2026-08-11 NCT03406611
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known…
Trial sites expanded: 8 -> 12 locations
2026-08-11 NCT03406611
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known…
date change Primary completion pushed: 2026-06 -> 2027-07
2026-08-11 NCT03406611
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known…
date change Completion pushed: 2026-12 -> 2027-07
Active Trials by Phase
Phase 4
1
Phase 3
3
Phase 2
1
Phase 1/2
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07219121 Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental… Proteinuria Active, Not Recruiting
Phase 3
NCT06247085 A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in… Homocystinuria Recruiting
NCT03762850 A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA… Immunoglobulin A Nephropathy Active, Not Recruiting
NCT06431893 A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase… Homocystinuria Enrolling by Invitation
Phase 2
NCT05003986 Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Focal Segmental Glomerulosclerosis Recruiting
Phase 1/2
NCT03406611 Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known… Homocystinuria Recruiting
Not specified
NCT02998710 Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency… Homocystinuria Due to CBS Deficiency Recruiting
Get alerts when Travere Therapeutics, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free